IMIO Raises $12M Led by Sofinnova Partners and Chipotle's Fund

IMIO has raised $12 million from Sofinnova Partners and Chipotle's Cultivate Next fund, according to an announcement carried by Yahoo Finance. The round pairs a European life-sciences investor with the corporate venture arm of one of America's largest restaurant chains.

The money will fund two things, the company said: scaling what it calls reliable biologicals and improving soil performance. In plain terms, IMIO works on biological crop products that behave predictably in the field — a persistent weak point for the agricultural biologicals sector.

Who is putting up the money?

Sofinnova Partners leads the list of backers. The Paris-based firm has decades of history financing life-science and sustainability companies, and its involvement signals IMIO is being treated as a biotechnology bet, not just an agtech one.

The second named investor is Cultivate Next, Chipotle Mexican Grill's venture fund. Chipotle launched Cultivate Next to back companies that can make its supply chain more sustainable, and an investment in soil performance fits that mandate directly. For Chipotle, healthier soil means more resilient ingredient sourcing — a supply-chain hedge as much as a financial position.

What will the $12M actually do?

Per the company's announcement, the capital goes toward:

• Scaling IMIO's biologicals products
• Improving soil performance where those products are deployed

The phrase "reliable biologicals" is the operative one. Farmers have long been skeptical of biological crop inputs because performance varies with soil, weather and storage conditions. A company that can make biologicals act consistently — closer to how synthetic inputs behave — addresses the sector's core credibility problem.

Why does a burrito chain care about soil?

Chipotle's involvement is the deal's most conspicuous detail. Restaurant chains face rising scrutiny over agricultural sourcing, and regenerative or soil-focused agriculture has become a favored corporate sustainability lever. Cultivate Next gives Chipotle both a window into emerging agtech and early access to tools that could improve the ingredients it buys at scale.

Sofinnova's participation suggests the round was underwritten on scientific substance. The firm's due diligence typically centers on product pipelines with defensible biology.

What comes next?

The announcement did not disclose a valuation, IMIO's revenue, or a deployment timeline for the funds. Those gaps leave the round's structure — equity, convertible, or otherwise — unstated in the release carried by Yahoo Finance.

The test ahead is field performance. If IMIO's biologicals deliver consistent soil and yield results at commercial scale, the company will have solved the problem that has kept biologicals a niche category. If not, $12 million buys a lot of trials but not a market.